ClinicalTrials.gov
ClinicalTrials.gov Menu

Clinical Study of the Treovance Stent-Graft for Patients With Abdominal Aortic Aneurysms

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02009644
Recruitment Status : Active, not recruiting
First Posted : December 12, 2013
Last Update Posted : December 20, 2017
Sponsor:
Information provided by (Responsible Party):
Bolton Medical

Brief Summary:
The purpose of this clinical trial is to assess and evaluate the safety and efficacy of the Treovance Stent-Graft with Navitel Delivery System in subjects with Abdominal Aortic Aneurysms (AAA).

Condition or disease Intervention/treatment Phase
Abdominal Aortic Aneurysm (AAA) Device: Subjects who receive the Treovance stent-graft Phase 2

Detailed Description:

This is a phase II, multi-center, non-blinded, non-randomized study of treatment with the Treovance Stent-Graft in subjects with abdominal aortic aneurysms. The study will include 150 subjects treated with the Treovance Stent-Graft at a maximum of 30 investigational sites. There will be no prospective control group. Subjects diagnosed with infrarenal abdominal aortic aneurysms enrolled in the trial will be treated with the Treovance Stent-Graft with Navitel Delivery System. Pre-procedure baseline data will be gathered, as well as post-procedure assessments prior to hospital discharge and 30 days, 6 months, and 12 months post-implantation. In addition, annual follow-up visits out to 5 years will be conducted.

The primary goal of this study is to gather safety and effectiveness data on the Treovance device. A maximum of 150 endovascular subjects will be required to fulfill the U.S. Phase II requirements. The data from this study will be submitted to the FDA and used to support approval in the U.S.

There are two primary objectives, efficacy and safety of the Treovance Stent-Graft in subjects with infrarenal aortic aneurysms:

  • Primary Efficacy will be evaluated by successful aneurysm treatment 12 months post-implant
  • Primary Safety will be assessed by composite major adverse event (MAE) rate at 30-days

Secondary objectives involve assessment of major device-related events and major morbidity.


Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 150 participants
Intervention Model: Single Group Assignment
Intervention Model Description: AAA Device
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase II Clinical Study of the Safety and Performance of the Treovance Stent-Graft With Navitel Delivery System for Patients With Infrarenal Abdominal Aortic Aneurysms
Study Start Date : November 2013
Actual Primary Completion Date : May 2017
Estimated Study Completion Date : June 2021

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Arm Intervention/treatment
Experimental: Treovance
Subjects who receive the Treovance stent-graft
Device: Subjects who receive the Treovance stent-graft
Eligible subjects will be implanted with the Treovance Stent-Graft
Other Name: Treovance Abdominal Stent-Graft with Navitel Delivery System



Primary Outcome Measures :
  1. Primary Efficacy [ Time Frame: 12 months ]
    Successful aneurysm treatment which is a composite of the following: Technical success at the conclusion of the procedure; absence of aneurysm enlargement; absence of device-related complications (e.g., fracture, conversion to open surgical repair, etc.)

  2. Primary Safety [ Time Frame: 30 days ]
    The primary safety endpoint is composite major adverse event (MAE) rate (including myocardial infarction, stroke, respiratory failure, etc.)


Secondary Outcome Measures :
  1. Secondary Safety Endpoint [ Time Frame: 30 days, 6 months, 12 months ]
    Secondary safety endpoints will include each individual rate for the adverse events included in the composite MAE at 30 days, 6 months, and annually.

  2. Secondary Efficacy Endpoint-- Secondary interventions [ Time Frame: 30 days, 6 months, annually ]
    The secondary efficacy endpoint includes the rate of additional procedures performed to correct the original implant

  3. Secondary Efficacy Endpoint -- Device-Related Complications [ Time Frame: 30 days, 6 months, and annually ]
    This endpoint includes the rate of complications associated with the device.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 85 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Subject must be diagnosed with an infrarenal abdominal aortic aneurysm (AAA), with or without iliac artery involvement
  • Subject must have an infrarenal AAA that is > 4.5 cm in diameter for males, or > 4.0 cm in diameter for females, or has increased in diameter by 0.5 cm in the last 6 months

Exclusion Criteria:

  • Subject has a dissection in abdominal aorta, ruptured aneurysm, or symptomatic aneurysm (as determined by treating physician)
  • Subject has had a prior AAA repair (endovascular or surgical)
  • Subject is participating in another research study, has received investigational study drug within 30 days of planned procedure, or has received an investigational device within one year of planned procedure

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02009644


  Show 32 Study Locations
Sponsors and Collaborators
Bolton Medical
Investigators
Principal Investigator: Matthew Eagleton, MD Cleveland Clinic Foundaton

Responsible Party: Bolton Medical
ClinicalTrials.gov Identifier: NCT02009644     History of Changes
Other Study ID Numbers: IP-0008-12
First Posted: December 12, 2013    Key Record Dates
Last Update Posted: December 20, 2017
Last Verified: December 2017

Keywords provided by Bolton Medical:
Abdominal Aortic Aneurysm
AAA
Aneurysm

Additional relevant MeSH terms:
Aneurysm
Aortic Aneurysm
Aortic Aneurysm, Abdominal
Vascular Diseases
Cardiovascular Diseases
Aortic Diseases